Afluria Quadrivalent is an inactivated influenza vaccine intended to protect patients against four different flu viruses — two Type A viruses and two Type B viruses. The vaccine comes in a single-dose pre-filled syringe.
In May, Seqirus received FDA approval for another quadrivalent flu vaccine called Flucelvax.
Afluria Quadrivalent will be available in the U.S. for this year’s flu season.
More articles on supply chain:
FDA fast tracks experimental drug to treat Parkinson’s
The rise of the unbranded drug ad: 5 things to know
Mylan to introduce generic EpiPen at half the price
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
